Turning tabular data into ‘pseudo-notes’ that mirror clinical documentation allows AI models to analyze patient information ...

The biggest challenge to AI initiatives is the data they rely on. More powerful computing and higher-capacity storage at lower cost has created a flood of ...

A June 27, 2025, Google study has uncovered serious quality issues in three of the most widely used public multilingual ...

The GCAptAIN study did not meet its primary endpoint of sustained remission at Week 52 in adults with newly diagnosed or relapsing GCA1Safety in GCA ...

If your child is evaluated for an IEP and found eligible, their eligibility will be in one of IDEA eligibility categories.

June brought major prostate cancer updates, and CURE is sharing the latest FDA approvals, label expansions, and emerging data ...

Nearly 1 in 5 packaged foods and drinks from major U.S. brands contain synthetic dyes, with products aimed at children—like ...

The chief data reporter for the Financial Times discusses how he considers the use of text, color, and annotation to aid ...

Basel: Roche has announced its decision to proceed with Phase III development of prasinezumab, an investigational anti-alpha-synuclein antibody, in early-stage Parkinson’s disease. This decision ...

Roche to advance prasinezumab into phase III development for early-stage Parkinson's disease: Basel Tuesday, June 17, 2025, 09:00 Hrs [IST] Roche announced its decision to proceed ...

Tiziana (TLSA) is showing groundbreaking advancements in Alzheimer's & MS treatments with foralumab. Key trials & market insights reveal exciting opportunities. See more.

-- Data being presented at the 32nd Annual FSHD Society International Research Congress (IRC); Investor and analyst webcast event today, Monday, June 9 at 8:00 a.m. ET-- SAN DIEGO, June 9, 2025 ...